Elutia Inc. (ELUT) 株式分析

企業概要

Elutia Inc. is a commercial-stage medical device enterprise dedicated to the development and commercialization of drug-eluting biomatrix products designed for surgical reconstruction and related clinical applications. The company operates within the broader healthcare sector, specifically focusing on the medical devices industry, which entails the manufacturing and distribution of instruments and implants essential for therapeutic procedures. Currently, the organization employs a workforce of 25 individuals and holds a market capitalization of $48.35M, with reported annual revenue (TTM) totaling $12.29M. These valuation and revenue metrics indicate that Elutia positions itself as a micro-cap entity operating with a lean operational structure, reflecting its stage of development and the capital-intensive nature of bringing specialized biomatrix technologies to market while maintaining a relatively small human resource footprint.

財務健全性

The company reported total revenue of $12.29M over the trailing twelve months, yet simultaneously recorded a net income loss of $15,871,000 and an EBITDA of $-17,196,000, highlighting a significant divergence where operational losses substantially exceed revenue generation. This gap between positive revenue and negative net income reveals a cost structure characterized by high operating expenses or non-operating charges that consume the entirety of top-line earnings before tax. Free cash flow stands at $-25,104,500, indicating that the company is currently burning cash, which implies limited financial flexibility for immediate expansion or without external capital injections. Despite the negative operating margin of -167.9% and a profit margin of 434.2%, the gross margin remains robust at 53.7%, suggesting that the core cost of goods sold is efficiently managed relative to sales price. On the liability side, Elutia holds $36.35M in cash against $3.94M in debt, resulting in a debt-to-equity ratio of 14.24 that suggests a highly leveraged balance sheet structure relative to equity. The current ratio of 2.22 indicates a strong position in short-term liquidity, demonstrating that current assets are more than twice the value of current liabilities. Additionally, the return on assets is -23.4% while return on equity is N/A, revealing that the management's effectiveness in generating returns from the asset base is currently negative due to the lack of profitability.

バリュエーション評価

The trailing twelve-month P/E ratio is N/A due to the absence of net income, while the forward P/E is recorded at -1.03, implying that the market anticipates earnings improvement in the future despite current losses. The price-to-book ratio is 1.75, indicating that the market values the company at a premium of 75% over its book value, which may reflect investor confidence in the pipeline's potential rather than current asset value. Alternative valuation metrics such as the price-to-sales ratio of 3.93 and an EV/EBITDA of -0.93 suggest that investors are pricing the stock based on revenue potential and enterprise value dynamics rather than earnings power. The stock has fluctuated between a 52-week low of $0.50 and a high of $2.74, meaning the current price sits significantly below the yearly peak, reflecting recent market corrections or lack of earnings support. With a beta of 0.71, the stock exhibits lower volatility relative to the broader market, suggesting that price movements are less sensitive to general market swings compared to high-beta equities.

Growth & Income

Revenue growth over the past year stands at 16.2%, whereas earnings growth is N/A because the company has not yet achieved profitability. Since earnings are not growing faster than revenue due to the absence of positive earnings, the top-line expansion is currently being consumed by costs rather than converting to bottom-line profit. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which indicates that all available cash is being reinvested into research and development or operational growth rather than distributed to shareholders. Consequently, the overall growth and income profile of Elutia is defined by revenue expansion without current income distribution, relying entirely on future commercial success of its lead programs like NXT-41 and NXT-41x to drive financial turnaround.